NuSep: NuSep set to transform IVF sector at Melbourne, Sydney Luncheons

Under the tiller of executive chairman, Alison Coutts NuSep (ASX:NSP) has improved their balance sheet and is entering clinical trials, in human IVF and animal (initially IVF).It is looking to transform IVF by taking male infertility head on and doing so more quickly, cheaply and with better results with its technology.Proactive Investors has secured executive chairman Alison Coutts to present to investors at the "Melbourne Investor Luncheon" on Tuesday 10th February and the "Sydney Investor Luncheon" on Wednesday 11th February.REGISTER by clicking on the city below for additional details: Melbourne OR Sydney. Otherwise call (02) 9299 5001(02) 9299 5001 and ask for John.NuSep's balance sheet has improved post the 19 Dec 2014 annual general meeting with over $4 million in debt converted to equity.The company's Net Asset position is now positive at about $2 million.NuSep has unique proprietary technology in biological separations that are proven to work with two major applications in sperm separation and human plasma (through investment in PrIME).It also offers multiple unique benefits over incumbent technology.Tansforming IVFNuSep's SpermSep is the first dedicated sperm selection device for the IVF industry.The devices select the healthiest, most viable sperm cells from semen samples quickly, cheaply, and with reduced sperm damage.This compares with current IVF processing which is a multi-stage, expensive, hands-on process performed by lab technicians.Current sperm preparation methods have disadvantages with the most common Density Gradient Centrifuge (DGC) method involving two damaging steps for sperm cells.Spermsep has a commercial solution to key male infertility issues with the company having already demonstrated proof of concept with the completion of small human IVF clinical trials.These in vitro trials documented the improved sperm selection and reduced DNA-damage using the SpermSep method.Male infertility is highly prevalent Male infertility is a factor in > 45% of infertile couples with about 5% of Australian men being infertile.This has been increasing over the past few decades with fertility issues being more common in odler men.There are also strong links between infertility and chronic disease.Expanding MarketThe Human IVF market is large and expanding with the market expected to grow to US$21.6 billion in 2020 from US$9.3 billion.In addition, the animal artificial reproduction market is also large with IVF used for elite, high value animals.This is rapidly expanding as emerging countries improve herd genetics.PrIME BiologicsNuSep also has a majority owned investment in PrIME Biologics Pte Ltd, Singapore, which is focused on the underserved Asian plasma.PrIME is preparing to commercially produce albumin and immunoglobulins from human blood serum.Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX "Small and Mid-cap" stocks with distribution in Australia, UK, North America and Hong Kong / China.